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Abstract
Vector-borne diseases impose enormous health and economic burdens and additional methods to control vector
populations are clearly needed. The Sterile Insect Technique (SIT) has been successful against agricultural pests, but is not in
large-scale use for suppressing or eliminating mosquito populations. Genetic RIDL technology (Release of Insects carrying a
Dominant Lethal) is a proposed modification that involves releasing insects that are homozygous for a repressible dominant
lethal genetic construct rather than being sterilized by irradiation, and could potentially overcome some technical
difficulties with the conventional SIT technology. Using the arboviral disease dengue as an example, we combine vector
population dynamics and epidemiological models to explore the effect of a program of RIDL releases on disease
transmission. We use these to derive a preliminary estimate of the potential cost-effectiveness of vector control by applying
estimates of the costs of SIT. We predict that this genetic control strategy could eliminate dengue rapidly from a human
community, and at lower expense (approximately US$ 2,30 per case averted) than the direct and indirect costs of disease
(mean US$ 86–190 per case of dengue). The theoretical framework has wider potential use; by appropriately adapting or
replacing each component of the framework (entomological, epidemiological, vector control bio-economics and health
economics), it could be applied to other vector-borne diseases or vector control strategies and extended to include other
health interventions.
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Introduction
Around the world, vector-borne diseases cause medical and
economic burdens as current control measures fail to cope, and
face possible negative effects of local environmental change. There
is a need to identify new or improved strategies that will remain
effective despite growing insecticide and drug resistance [1].
Genetic techniques targeting insect vectors may provide new
approaches to disease control; to illustrate their potential benefit,
we focus on dengue, arguably the most important arboviral disease
of humans.
Dengue is potentially severe, although it can present as a
spectrum of symptoms from near-asymptomatic or mild febrile
illness, through the classic incapacitating disease (seldom fatal), to its
most severe forms dengue hemorrhagic fever (DHF) and dengue
shock syndrome (DSS) [2]. Case fatality rates for DHF range from
below 1% with modern intensive supportive therapy to over 20%
without proper treatment, averaging 5% worldwide [3]. Dengue,
the most rapidly spreading vector-borne disease in the tropics and
subtropics, is endemic in over 100 (mainly low and middle income)
countries and over 40% of the world’s population live in areas at
risk. An estimated 50–100 million infections occur annually; an
annual average of over 0.9 million severe cases are reported to
the World Health Organization (WHO) and roughly 18–19,000
dengue-relateddeathsareregisteredeachyear[2,4,5,6].Allagesare
affected, with most deaths and cases reported to WHO occurring
among children (age 0–14 years) [4,6].
Dengue is caused by any of four related flaviviruses. All four
of these dengue virus serotypes are circulating in Asia, Africa and
the Americas [5], though not all in all countries. Infection with
any one serotype confers lifelong immunity to that type, and
temporary cross-immunity to other serotypes [3,7]. On subsequent
heterotypic infection after cross-immunity wanes, antibody-
dependent enhancement (ADE) increases the risk of more serious
disease (and DHF) [3,8]. Dengue is transmitted by the bite of an
infective female mosquito; the main vector is the yellow fever
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Aedes albopictus implicated as a secondary vector in some areas.
There are currently no drugs for dengue, and an effective and
safe vaccine is unlikely to be available for several years [9,10]. The
Aedes vectors principally bite during daylight [11], and although
preliminary evidence suggests that insecticide-treated bednets might
provide some protection against dengue, studies with insecticide-
treated materials (e.g. curtains, water container covers) have had
mixed results [12,13]. The only practical prevention method
presently available is to control the principal vector. Current efforts
focus on mosquito control and larval source reduction [4,14,15].
Complexurban settings present a majorchallenge for vector control
activities, and in practice their effectiveness has been compromised
due to issues of delivery, coverage and acceptability [2,5,16].
Dengueisa suitable targetforgeneticvector control strategiesasitis
specific to humans across most of its range (it has no significant
animal reservoirs), has a single dominant vector, and area-wide
vector control programs have in the past proven to be effective in
controlling this disease, although those methods are now unaccept-
able or have not been sustainable [17,18].
The Sterile Insect Technique (SIT) has been used successfully
for suppressing or eliminating a number of agricultural pests [19],
but there are no large-scale SIT programs in operation against any
mosquito species. A number of trials were conducted against
mosquitoes mostly in the 1960s and 1970s, and in recent years
extensive research and development has been underway in
preparation for commercial scale SIT [20,21,22]. Some technical
difficulties with SIT using radiation-sterilization can potentially be
overcome using genetically engineered strains, particularly loss of
male fitness and absence of sex-separation mechanisms applicable
on a large scale (which are necessary to release only males, as even
sterile female mosquitoes bite) [21,23,24,25]. Recently, Ae. aegypti
mosquitoes suitable for use in the RIDL (Release of Insects
Carrying a Dominant Lethal) system have been developed by
transformation with repressible, dominant, late-acting, bisex-lethal
genetic constructs (causing death after the effects of density-
dependent larval mortality) [26]; such strains are the subject of this
paper. This system has an in-built element of resistance dilution,
which a theoretical study suggests can protect against the evolution
of resistance to the genetic lethal construct [27].
An initial assessment of the potential impact of RIDL strategies
on a generic mosquito-borne disease, using a simple mathematical
model [28], suggested it is feasible to eliminate the disease from a
human population of order 10
6 in roughly one year. There is a
trade-off between the time to virus eradication and the total
number of mosquitoes released, which has economic implications.
Numerous studies (see Supporting Information S1 & Table S3)
report estimated costs of dengue in various countries from 1977 to
2005, mainly during epidemics, but these vary in details, methods,
timing and the nature of costs included. Often these studies
underestimate the true economic impact as they omit effects such
as lost productivity, time off work or school, social disruption and
lost tourism [2]. A prospective study [29] applying a common
protocol in eight countries, is the most comprehensive study of
dengue costs published to date and the first to develop comparable
data over two hemispheres.
Dengue vector control in urban areas with current methods is
costly [15]. Here we develop a combined model framework to
analyze the approximate economic cost-effectiveness of genetic
vector control (Figure 1). A mosquito population dynamics model
predicts the population size of the vector (adult female mosqui-
toes). This is coupled with an epidemiological model to predict the
disease dynamics, including the total number of dengue cases. This
combined model captures key features, including density-depen-
dent competition among Ae. aegypti larvae and the multi-annual
cycles that are characteristic of dengue. It is not intended to be a
comprehensive representation of the interaction between mosquito
vectors, disease virus and humans, and we simplify the model
components appropriately. For example, we ignore within-year
seasonal fluctuations as modeling suggests these are unlikely to
have a significant effect on multi-year patterns of incidence [30],
we do not incorporate spatial heterogeneity, and we assume
random mating among mosquitoes. We apply estimates of the
costs of RIDL-based SIT for vector control, based on data for
irradiation-based SIT, to investigate the potential cost-effective-
ness of this strategy.
Methods
The full derivation of the vector population dynamics and
epidemiological models is set out in the Supporting Information
S1. The state variables are listed in Table 1 and all parameters
described in Table 2.
Vector population dynamics model
We modify a simulation model for the population dynamics of
Ae. aegypti developed by Dye [31], who used data from field studies
Figure 1. Overview of model components.
doi:10.1371/journal.pone.0025384.g001
Genetic Vector Control against Dengue
PLoS ONE | www.plosone.org 2 October 2011 | Volume 6 | Issue 10 | e25384Table 1. State variables.
Vectors (adult female
mosquitoes):
F total number of adult female vectors (susceptible, exposed and infectious)
X susceptible
Yj infectious with serotype j
Hosts (humans):
N total number of hosts (susceptible, exposed, infectious, cross-immune and recovered)
S susceptible to all serotypes
Ii primary infection (infectious) with serotype i
Ci recovered from primary infection with serotype i, temporarily cross-immune to all other types
Ri recovered from primary infection with serotype i, susceptible to all other types
Iij secondary infection with serotype j, following primary infection with serotype i
R recovered from secondary infection, immune to all serotypes
doi:10.1371/journal.pone.0025384.t001
Table 2. Parameters.
Symbol Description Default value Range Refs.
s Adult mosquito death rate (per day) 1/14 (chosen to
be conservative)
1/15 to 1/3 [3,30,33,55,56,57,58,59,60]
T Mosquito generation time (days), i.e. development period from egg
to emerging adult
18.5 16.9–20.1 [3,31,32]
E Daily egg production rate per adult mosquito (a female lays 2E per
day on average, a male lays none)
8 7–9 [31,32,33]
P The number of offspring produced by each adult per day that
will survive to adulthood in the absence of density-dependent
mortality (i.e. E adjusted for density-independent egg-to-adult
survival)–estimated value, calculated using field data, depends
on value of s (P/s is net reproductive rate)
0.7 0.2 to 0.7 [31,32,33]
k Average number of vectors (adult female mosquitoes) per host
(initial population N0)
2 0.3 to 20 [3,11,58,61]
a 1/a is related to the number of breeding sites. Set
a = log(P/s)/[(2kN0E)
b] for given initial host population (N0)
<1.5 610
28 <4.5 610
212
to <1.0 610
22
[31]
b Strength of larval density dependence 1 0.302 to 1.5 [31,50]
C Maintained ratio of RIDL males to pre-release equilibrium number
of adult males (constant release policy)
10 or 1 various N/A
n Human per capita birth rate (per day) Equal to human death rate 1/(606365) 1/(606365) to 1/(686365) N/A
m Human per capita death rate (per day) i.e. 60 year life span (default) 1/(606365) 1/(606365) to 1/(686365)
Thailand 1974–2010
[62,63,64]
b Biting rate (number of bites per mosquito per day) 0.5 0.33 to 1 [58,65]
a Proportion of bites that successfully infect a susceptible human 0.38 0.25 to 0.75 [30,66]
c Proportion of bites that successfully infect a susceptible mosquito 0.38 0.20 to 0.75 [30,66,67]
t Virus latent period in humans (days) Intrinsic incubation period 5 3 to 12 [7,68]
v Virus latent period in vectors (days) Extrinsic incubation period 10 7 to 14 [3,7,66,68]
c Human recovery rate (per day) i.e. infectious period 6 days (default) 1/61 /10 to 1/2 [3,7,29,68]
y Rate at which humans lose cross-immunity (per day)
i.e. cross-immunity lasts 4 months (default)
1/(36564/12) 1/(36565/12) to 1/(36562/12) [3,7,30]
x Increased host susceptibility due to ADE 1.5 1 to 3 [3,30]
f (Alternative to x) Increased transmissibility due to ADE 1 1 [3]
r Proportion of hosts that recover from secondary infection
(1-r die from DHF/DSS)
0.9999 120.056(120.87) < 0.9935 to 1 [3,29,37]
doi:10.1371/journal.pone.0025384.t002
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Designating the number of vectors, i.e. female adult mosquitoes, at
time t as F(t), prior to the start of releases we use a delayed
differential equation comprising an adult mortality term and a
term for adult emergence that incorporates both density-
independent mortality of immature stages and a two-parameter
function representing density-dependent larval mortality (equation
S1). The number of vectors naturally settles at, or oscillates
around, an equilibrium value F (equation S2; in deriving this we
define k as the average number of vectors per host prior to
control); if the numbers were perturbed they would increase (or
decrease) back to equilibrium if density dependent competition
among larvae were weak (i.e. low parameter b much smaller than
1), return to equilibrium overshooting back and forth on the way
(damped oscillations with intermediate b) , or revert to oscillating
around the equilibrium (strong density dependence, high b). We
modify equation S1 to incorporate the release, starting at time
t~0, of homozygous male mosquitoes that carry a dominant, late-
acting, bisex-lethal genetic construct (‘‘RIDL males’’, whose
progeny die as late larvae after the effects of density-dependent
larval mortality). Mass-reared adult RIDL males are released in
quantities that maintain their numbers at a fixed ratio (the ‘‘release
ratio’’ C) to the natural equilibrium number of adult males or
females in the wild population, i.e. the total number of adult RIDL
males ~CF  for tw0. Only the larvae sired by wild type males
survive to emerge as adults, so the adult emergence rate is
proportionally reduced, assuming random mating.
dF
dt
~PF(t{T)
F(t{T)
F(t{T)z~ C CF  exp {a 2EF(t{T) ½ 
b
no
{sF ð1Þ
where ~ C C~
0
C
8
<
:
t{Tƒ0
t{Tw0
Epidemiological model
In conjunction with the vector population dynamics model, we
use a compartmental epidemiological model to describe the status
of vectors and hosts with respect to the disease. Vectors, the adult
female mosquitoes, are classed as susceptible (X) or infectious (Yi),
and human hosts (N) are classed broadly as susceptible (S
susceptible to all types, or Ri, recovered from serotype i and
susceptible to other types), infectious (Ii primary infection, or Iji
secondary infection with serotype i after past infection by type j),
cross-immune (Ci, not to be confused with C, the release ratio) or
recovered (R). The intrinsic (in the host) and extrinsic (in the
vector) incubation periods are represented using fixed duration
time delays. The choice and range of values for entomological and
epidemiological parameters is drawn from published literature
(Table 2).
Full representation of all four dengue serotypes and the
interactions between them requires a complicated mathematical
model. To reduce the complexity we restrict the model to two
serotypes. We label these i =1 and 2, which could be any pair of
the four known serotypes. ADE manifests both as increased
susceptibility to a secondary infection (xw1), and as a risk of DHF
or DSS from secondary infection, with a proportion (1{r) dying
at the end of the infectious period. Although ADE may manifest
as increased transmissibility from a host with a secondary infec-
tion (fw1), we do not use this alternative in our simulations
(we keep f~1); other authors found predictions from a similar
model insensitive to whether ADE acts through transmissibility or
susceptibility [30]. Together, equations 1 to 10 (given below) form
a system of delay-differential equations representing the vector-
pathogen-host dynamics.
dX
dt
~PF(t{T)
F(t{T)
F(t{T)z~ C CF  exp {a 2F(t{T)E ½ 
b
no
{cb
X
N
I1zfI21zI2zfI12 ðÞ {sX
ð2Þ
dYi
dt
~ exp({sv) ðÞ
cbX(t{v)
N(t{v)
Ii(t{v)zfIji(t{v)
  
  
{sYi i,j~1,2; j=i
ð3Þ
dS
dt
~nN{
X 2
i~1
ab
F
N
S
Yi
F
  
{mS~nN{ ab
S(Y1zY2)
N
  
{mSð4Þ
dIi
dt
~ exp({mt) ðÞ ab
S(t{t)Yi(t{t)
N(t{t)
{(czm)Ii i~1,2 ð5Þ
dCi
dt
~cIi{ yzm ðÞ Ci i~1,2 ð6Þ
dRi
dt
~yCi{ xab
RiYj
N
  
{mRi. .
.
i,j~1,2; j=i ð7Þ
dIij
dt
~ exp({mt) ðÞ xab
Ri(t{t)Yj(t{t)
N(t{t)
{(czm)Iij
i,j~1,2; j=i
ð8Þ
dR
dt
~ rc(I12zI21) ðÞ {mR ð9Þ
dN
dt
~nN{ (1{r)c(I12zI21) ðÞ {mN ð10Þ
The two serotype model encapsulates the key properties of the
disease dynamics. We use it to evaluate the RIDL genetic strategy
for vector control by modeling the potential reduction in numbers
of cases. Fewer cases will reduce the cost and burden of disease.
The release ratio and duration of release of engineered male
mosquitoes will drive the costs of the intervention.
We tested the sensitivity of our vector-epidemiological mo-
del to parameter values in the ranges shown in Table 2, for re-
lease ratio (C) 10, which is projected to achieve vector elimination,
and initial human population 2 million (see Supporting Informa-
tion S1).
Estimating costs and assessing cost-effectiveness
The cost-effectiveness of any disease control strategy is the cost
of achieving a specified outcome. For our study, we compare the
projected costs per case averted by genetic vector control with
estimates of the average cost of an episode of illness.
Genetic Vector Control against Dengue
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dollars; where this is not so we convert using published exchange
rates [34]. We inflate values to 2008 US dollars using GDP
chained Price Index [35]. Drawing information from the available
literature and various public sources, we identify SIT facility
construction costs (Table S1) separately from operational costs
(Table S2) where possible and attempt to fit regression curves to
the available data for each, using a non-linear least-squares
approach. This information is applied to generate a range of
projected values for those two key broad elements of SIT cost. We
use total cases, output from the simulation model, as our measure
of the direct impact of the disease. The cost of dengue is estimated
using a range of values for cost per case, based on published
studies (Table S3). We also gather data on the per capita cost of
conventional vector control methods (Table S4).
Results
Vector population dynamics
With our assumption that the vector population starts at, or
oscillating around, its natural equilibrium F , a sufficiently high
release ratio (CwCR a threshold value) will eliminate the local
vector population (F=0), or a lower release ratio (CƒCR) will
suppress the vector population to a new, smaller, stable
equilibrium, which decreases as C increases towards CR. These
results are independent of scale (i.e. size of host and vector
populations); only the ratio of the post-release equilibriumF 
R to
the pre-release equilibrium F  is relevant. With default parameter
values (as in Table 2) the critical release ratio CR is approximately
1.19 (i.e. maintain 1.19 RIDL males for every wild type male at
pre-release equilibrium), which will reduce the vector population
to a new steady size a little over a third of its equilibrium before
releases had started (F 
R is approximately 0.34 times F ).
Epidemiology (no RIDL release)
The two serotype model exhibits characteristic epidemic cycles,
with average period of c.5.5 years. (Four serotypes would be about
3.3–3.6 years per epidemic, in line with a 30-year four-serotype
dataset from Thailand and a full four-serotype model [30]). Once
the pattern is established, about 60% of the host population is
recovered and immune to both serotypes.
The model can be analyzed in part by applying ecological and
population biology techniques. For simplicity, we may assume the
vector population is at equilibrium (F ), and the host birth (n) and
death (m) rates are equal and dengue-associated deaths are
negligible (r&1) so that the host population (N) is constant. We
can estimate the value of R0 inherent in our model from a dengue-
naı ¨ve scenario, either from first principles or using mathematical
methods (see Supporting Information S1):
R0~
e{(svzmt)acb2
s(czm)
F
N
&
e{(svzmt)acb2k
s(czm)
ð11Þ
With our default parameter values (Table 2), this estimated R0 is
approximately 3.
With constant host population, we can assess the conditions
under which dengue (one serotype) can invade naı ¨ve populations
(where all hosts and vectors are susceptible to dengue, S&N and
X&F &kN, where k is the average number of vectors per host at
equilibrium) by expressing equations 3 and 5 in the form of an
invasion matrix (see Supporting Information S1). This method
gives the entomological threshold for disease transmission, i.e. the
minimum number of vectors (adult female mosquitoes) per host in
a susceptible population that are necessary to sustain the disease,
which we label kd:
kd~
sc zm ðÞ esvzmt
cab2 ð12Þ
With default parameter values (Table 2), kd&0:7. Simula-
tions with a reasonable estimate of mortality from DHF/DSS
(r~0:9999, Table 2), confirm the entomological threshold is still
approximately 0.7. The invasion threshold is where the basic
reproduction number of dengue (R0) is equal to one [36].
These estimates for the basic reproduction number R0 and the
entomological threshold kd are validated by comparison with other
studies (Supporting Information S1).
Control of dengue by release of RIDL mosquitoes
There are potentially three possible scenarios:
N with sufficiently high release ratio (CwCR), the vector and
virus are eliminated (Figure 2);
N with intermediate release ratio (CƒCR), if the new equilibri-
um to which the vector population is reduced (F 
R) is below the
threshold of vector abundance needed to sustain transmission
(kdN), the virus is eliminated (equivalently,
F 
R
N
vkd in terms of
vectors per host);
N with too low release ratio (CƒCR), if the vector population is
reduced but remains above the transmission threshold vector
abundance (kdN) (i.e. vectors per host
F 
R
N
wkd), the virus may
temporarily fade out but the disease persists in the longer term
(Figure 3).
In practice, these thresholds (CR and kd) would be dynamic (e.g.
due to immigration/emigration, fluctuating parameter values,
and the effects of spatial heterogeneity), but these three potential
outcomes would still apply for generically ‘‘sufficiently high’’,
‘‘intermediate’’ or ‘‘too low’’ release ratios.
If the minimum possible non-zero equilibrium of vectors per
host (with the value of F 
R corresponding to critical release ratio
CR) is more than kd, the intermediate scenario cannot occur so we
could only eliminate the disease by eliminating the vector. This is
the case with our default parameter values, under the assumptions
of our models; in simulations a critical release ratio somewhere
between 1.1 and 1.2 determines whether both or neither vector
and virus are eliminated (this is comparable with the 1.19
calculated for the situation where there is no DHF/DSS
mortality). However, with only 1 vector per host (k), and release
ratio 1 (C), for example, the vector population is only reduced to
54% of its pre-release equilibrium value but this is enough to
disrupt transmission of the disease and eliminate the virus.
Without eliminating the virus, it is possible to reduce the disease
below detectable levels and sustain this by continued releases for
more than 50 years with our default parameter values and release
ratio 1 (Figure 3C). In our model this occurs as the numbers of
infectious hosts and vectors fall to very small values before
resurgence. In practice, the virus might temporarily fade out but
be reintroduced by an infectious person or vector joining the
population.
Entomological and epidemiological parameter values influence
the transmission threshold number of vectors per host (kd) and are
involved in determining whether there is any intermediate level of
control that only suppresses the vector and yet eliminates the
disease. In practice, it is likely that a control program would aim to
eliminate the vector if that were feasible. Uncertainty in measuring
parameters in the field, and deviations from model assumptions,
Genetic Vector Control against Dengue
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ratio 10:1. Release ratio C: 10. Over time (A) total number of vectors, (B)
total number of infectious hosts (primary or secondary infections), by
serotype (1: solid line, 2: dashed), (C) total number of hosts recovered
fromsecondary infection(solid)orsusceptibletoeitherorbothserotypes
(dashed). Default parameter values (Table 2), with initial conditions host
population N0: 2 million andprimary infections I1:1 ,I2: 2.Therelease ratio
is sufficientlyhigh (CwCR),that thevectorandvirusareeliminated.Over
subsequent years, immunity is lost from the host population.
doi:10.1371/journal.pone.0025384.g002
Figure 3. Vector and epidemiological dynamics, with release ratio
1:1. Release ratio C: 1. Over time (A) total number of vectors, (B & C) total
number of infectious hosts (primary or secondary infections), by serotype
(1: solid line, 2: dashed); Default parameter values (Table 2), with initial
conditions host population N0: 2 million and primary infections I1:1 ,I2:2 .
With this low release ratio (CƒCR), the vector population is reduced but
remains above the transmission threshold vector abundance (kdN); panel
(C) is on different scales (note the much longer time period) and shows that
the disease returns after initial suppression and persists in the longer term.
doi:10.1371/journal.pone.0025384.g003
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ratio.
We simulated the effect of RIDL male release in a dengue-
endemic setting; because the simulated costs do not scale linearly
with host or vector population sizes, we present results with initial
human population size of either 2,000,000 (Figures 2 & 3) or
10,000. In terms of scale, these numbers of people might represent
a city or small settlement, respectively, although our models do not
reflect the different spatial heterogeneities and different scale of
some implementation activities that would arise. With default
parameter values, the number of infectious hosts peaks at below
10% of the host population (e.g. under 2,000 in the city, Figure 2B),
with the mean proportion of infectious hosts just below half that
(e.g. mean number 800 in the city setting), corresponding to
disease incidence of under 2.5% per year on average (e.g. average
48–49,000 annual cases in a population of 2 million). We assessed
the outcomes-the average number of infectious cases arising in a
specified number of years from the start of RIDL releases and in
the equivalent period with no releases (C~0) - for a program
running for 5 or 10 years (Table 3), ignoring any residual effects
beyond that period.
As noted above, the high release ratio (C=10) eliminates the
vector and the virus, and although the low release ratio (C=1) only
suppresses the vector population and temporarily removes the
disease, continuing releases at this low level gives protection for
many years beyond the end of our assessment period (and beyond
the practical duration of any genetic vector control program). If
the disease is removed from (or barely present in) the host
population, the herd immunity reduces over time as immune hosts
die and are replaced by susceptible newborns (shown in Figure 2C).
When this happens, the effective transmission threshold reduces
over time (and the effective reproduction number Rt increases
towards R0) and if the vector population has not been suppressed
below the critical threshold for a susceptible population, the
disease can eventually rebound strongly (Figure 3C); this is thought
to have been a factor in the resurgence of dengue in Singapore
despite strong vector control [18]. Assessed strictly over a 5 or 10
year time frame, the two release regimes have very similar effects
and this is true in both settings. Where the vector is eliminated, this
is projected to occur in under a year, and our model suggests the
disease could be eliminated in three to six months. (The disease
can be eliminated earlier than the vector, because this can occur
soon after the vector falls below the transmission threshold.)
Production of RIDL males on this scale is potentially feasible,
even applying release ratio 10 in a city of 2 million, which would
require just over 1 billion RIDL males to be released annually over
the duration of the program. For comparison, the largest SIT
facility in the world, at El Pino in Guatemala, produces over 2
billion sterile male Mediterranean fruit flies per week [19],
equivalent to over 100 billion annually.
Estimated cost-effectiveness of genetic vector control
Using published data on SIT facility construction costs, we fitted
models of construction cost of facility (including radiation source)
against production capacity (see Supporting Information S1 &
Table S1). For facility scale commensurate with our results above,
our best fit was a rational function of the weekly production
capacity (equation S8). There is no such discernable pattern to
data on budgeted or actual operational or production costs for SIT
facilities to relate the cost per million insects to the production
quantity (see Supporting Information S1 & Table S2). We used the
mean cost (US$813 per million insects), and a range from the
minimum (US$172 for mosquito SIT in India in 1971) to the
mean plus standard error of the data (US$813+819 = US$1632).
Table 4 shows these projected costs applied to the simulated
numbers of insects released and assessed against the simulated
number of cases averted. Cases averted beyond the end of the
program period are ignored. The unit cost is of the order of
magnitude US$1 per 1000 insects in all scenarios simulated. The
mean cost per case averted is roughly US$2–3 with release ratio 1
and $US20–30 with release ratio 10 (in health economic terms,
these are average cost-effectiveness ratios, see points below
on incremental cost-effectiveness). The mean cost per person
Table 3. Simulation results.
Initial host population N0
2,000,000 10,000
Release ratio C 11 0 1 1 0
Time to vector elimination (days) N/A 285 N/A 211
Time to disease elimination (days) N/A 176 N/A 107
Mean numbers of infectious hosts with no release program, t:0t o+5 years 813 813 4 4
Mean numbers of infectious hosts with release program, t:0t o+5 years 25 13 0 0
Cases averted in 5 years
{ 239,816 243,532 1,146 1,179
Mean numbers of infectious hosts with no release program, t:0t o+10 years 815 815 4 4
Mean numbers of infectious hosts with release program, t:0t o+10 years 13 6 0 0
Cases averted in 10 years
{ 487,947 491,664 2,370 2,403
RIDL males released (millions) initially (CF
*) 4 40 0.02 0.2
RIDL males released (millions) per year (365sCF
*) 104.3 1042.9 0.5 5.2
Total released in 5 years (millions) 525.4 5254.3 2.6 26.3
Total released in 10 years (millions) 1046.8 10468.6 5.2 52.3
RIDL males released each week per person 1.0 10.0 1.0 10.0
{The average duration of infection is 6 days (1=c), i.e.
6
365
years, so an average of n infectious hosts at any time represents an average of nc~
365n
6
cases of infection per
year. The cases averted are therefore calculated as ([mean no. with no releases–mean no. with releases]/average duration) 6no. years.
doi:10.1371/journal.pone.0025384.t003
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or US$0.52–0.68 (release ratio 1 or 10, respectively).
Figure 4 shows the sensitivity of the costs per case averted to
changes in parameter value estimates. The impact on that measure
of outcome is generally smaller for the 10-year program as the
increased construction cost, where a larger capacity facility is
needed, is spread over a larger number of cases averted during the
longer period. Increasing the number of vectors per host (k) has the
largest effect, followed by the transmission rates in each direction
(a, c). In all these three instances, the effect arises mainly because
fewer cases are averted. These parameter value changes alter the
epidemic pattern, shortening the period between epidemics. This
change in timing means that without RIDL releases there are
fewer infections in our reference period than our default scenario
(fewer available to be averted by the intervention), and time t~0
happens to coincide with the (higher) peak of infectious cases,
consequently it takes two weeks longer to eliminate the virus.
Higher transmission rates also decrease the entomological
transmission threshold (kd), so the virus does not lose its potential
to spread until the vector population reaches that lower level.
Increasing the daily mortality rate of adult mosquitoes (s) has only
a small net effect. It increases the costs of RIDL releases, because
the population of RIDL males must be replenished at a faster rate,
which requires higher facility production capacity and output (this
effect is also shown separately, and the relative change in outcome
scaled to the relative change in parameter value is below 1 due to
the economies of scale in SIT costs). Increasing s by 5% raises the
entomological transmission threshold (kd) by about 9% (equation
12), so that the virus’s reproduction number falls below one when
the vector population is higher than in our default scenario and the
virus is eliminated more quickly.
Estimated benefits of reducing the burden of disease
Table S3 shows the range of dengue costs reported in various
studies (see Supporting Information S1). Several of these
underestimate the cost per case of illness–and therefore of the
potential value of the benefit of reducing the number of cases–as
they only include hospitalized cases, define costs narrowly and/or
adopt a patient not societal perspective. A recent, comprehensive
and consistent, prospective study across eight countries into the
costs of dengue [29], estimated average costs per clinically ill case
of US$ 357 (Asia) to US$793 (Americas). This study distinguished
between ambulatory and hospitalized cases, and included direct
medical costs, direct non-medical costs (such as transportation,
food and lodging associated with seeking or obtaining medical
care) and some indirect costs (days of school or paid work lost by
the patient or a household member providing care during the
illness episode). The lowest societal perspective cost reported is
US$59 for the 1994 epidemic in Nicaragua [15].
The costs apply mainly to cases that are clinically ill. About 76%
of dengue infections are thought to be asymptomatic or mild, and
24% of cases are clinically ill [37], although the few long-term
prospective cohort studies from 1980 to the present report ratios of
apparent cases to inapparent infections (without clinical signs) at
Table 4. Estimated cost of simulated releases.
Initial host population N0
2,000,000 10,000
Release ratio C 11 0 11 0
RIDL males released (millions) per week (7sCF
*)=
production capacity (x)
2.000 20.000 0.010 0.100
Construction costs 0.1297x/(1+0.0157x)( U S $ millions) 0.252 1.974 0.001 0.013
Five year program:
Total released in 5 years (z) 525.4 5254.3 2.6 26.3
Operational costs: mean 813z 0.427 4.272 0.002 0.021
Operational costs: range 172z to 1632z 0.090–0.857 0.904–8.575 0.000–0.004 0.005–0.013
Total (construction + operational) costs: mean 0.679 6.246 0.003 0.034
Total (construction + operational) costs: range 0.342–1.109 2.878–10.549 0.002–0.006 0.018–0.056
Cases averted in 5 years 239,816 243,532 1,146 1,179
Cost per case averted (mean) US$2.83 US$25.65 US$3.00 US$29.11
Incremental cost-effectiveness ratio N/A US$1498 N/A US$939
Ten year program:
Total released in 10 years (z) 1046.8 10468.6 5.2 52.3
Operational costs: mean 813z 0.851 8.511 0.004 0.043
Operational costs: range 172z to 1632z 0.180–1.708 1.801–17.085 0.001–0.008 0.009–0.085
Total (construction + operational) costs: mean 1.103 10.485 0.005 0.056
Total (construction + operational) costs: range 0.432–1.960 3.775–19.059 0.002–0.009 0.022–0.098
Cases averted in 10 years 487,947 491,664 2,370 2,403
Cost per case averted (mean) US$2.26 US$21.33 US$2.34 US$23.10
Incremental cost-effectiveness ratio N/A US$2524 N/A US$1545
Numbers of insects released and cases averted are taken from Table 3. All costs are in 2008 US$ millions, except the mean costs per case averted and incremental cost-
effectiveness ratio (which are in 2008 US$). The incremental cost-effectiveness ratio of 10:1 release compared to 1:1 release is the extra cost (total cost of the C~10
program minus that of the C~1 program) divided by the extra cases averted (cases averted with C~10 minus cases averted with C~1).
doi:10.1371/journal.pone.0025384.t004
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to 1.7:1 [3]. If only 24% of the infectious hosts simulated in our
model incur these costs of illness and the rest incur no cost, the
overall average cost per case (of any severity) is US$86–190 (based
on US$357–793 per clinically ill case), or perhaps as little as
US$14.16 (based on US$59). These all substantially exceed the
US$2–3 average cost of RIDL-based vector control per case
averted assuming the lower release ratio (C=1) and the likely
range significantly exceeds the US$20–30 average cost per case
averted with high release ratio (C=10).
As well as the average cost-effectiveness values discussed above,
it is appropriate to consider the incremental cost-effectiveness ratio
(ICER) of a program with release ratio 10 compared with a
program with release ratio 1. This indicator reflects the marginal
costs of the additional insects released and the extra benefit
obtained by doing so. The ICERs shown in Table 4 range from
US$939 to US$2524, which exceed the overall average societal
cost per infection US$86–190, so using our measure (cases averted
during the 5 or 10 year period) the extra cost of the higher release
ratio is not worth the additional health effects obtained by
disrupting virus transmission more quickly. In all four illustrated
scenarios, the release ratio 1 program is preferred.
A significant reduction of dengue prevalence, or local
elimination, might be expected to result in much lower
conventional mosquito control costs (and remaining costs such as
some surveillance are already included in our SIT cost estimates).
Using data on the cost of vector control measures (e.g. spraying
adulticides, larviciding, in some cases including costs such as
packing, transport, training and supervision) of varying effective-
ness, in a range of countries (Table S4), we estimate a mean annual
per capita cost of $0.765. Using this value, annual vector control
costs in the example of our simulated city of 2 million people
would be US$1.53 million and for 10,000 people would be
US$7,650. A major proportion of this would likely be saved, in
addition to the direct and indirect costs of illness shown above, but
the amount cannot be quantified from the available data.
Discussion
We have shown by mathematical modeling (subject to caveats
and model limitations discussed below) that genetic control of the
dengue vector, using RIDL male releases in a SIT program, can
eliminate the disease at a lower cost than the direct and indirect
cost savings from the illnesses averted. Our model suggests this
disease can effectively be removed from the population in a time
scale of the order of six months or less. This can be achieved even
where the vector is not suppressed to a level below the
entomological threshold for disease transmission, provided there
is sufficient disruption to transmission. Continuing the program of
releases can provide effective protection for many years beyond
the five or ten year assessment period. Wider benefits to the
economy (such as future productivity gains resulting from lives
saved, or increased tourism revenues) will clearly arise but have
not been quantified.
We have assumed that the genetic construct is 100% lethal and
that released RIDL males are fully competitive and available to
take part in mating. Generally, of all transgenic insertion lines
created, only those with sufficiently close to 100% lethality in
heterozygous form are chosen for further development; those
undergo tests for traits such as mating competitiveness, and only
successful lines progress through the phases. In diverse species,
lethality achieved by a single copy of a bisex-lethal or female-lethal
RIDL construct has been 97–100% [26,43,44,45]. The OX513A
bisex-lethal RIDL strain of Aedes aegypti (first described in [26]),
which is a lead candidate for field implementation, appeared to be
fully competitive in trials under semi-field conditions in Malaysia
Figure 4. Importance of different parameter values to cost per dengue case averted. Relative change in cost per dengue case averted as a
result of increasing each parameter value, one at a time, by 5%, for 5 year (black) or 10 year (white) release program. This is shown as ‘‘standard
elasticity’’, i.e. the relative change in the cost per case averted divided by the 5% relative change in each parameter value. Default parameter values
(Table 2), initial host population N0: 2 million, and release ratio C: 10.
1C was increased by 5% only in the calculations of cost, with the effective release
ratio kept at 10 in the epidemiological model, to represent losses during delivery of engineered males.
2We also tested a 5% increase in the mosquito
mortality rate s for males only, which affects the numbers to be released and hence the program costs.
doi:10.1371/journal.pone.0025384.g004
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in other species; one transgenic line of Mediterranean fruit fly
Ceratitis capitata exhibits 100% embryonic lethality and is described
as highly competitive with wild type Medfly in laboratory and field
cage tests [47]. For field use, the mosquito strain to be released is
made more similar to the local population by introgressing the
transgene into the appropriate genetic background (OX513A
exists in several genetic backgrounds). Although reductions in
lethality and mating competitiveness are expected to be low, losses
during handling and distribution might be more significant; any of
these would require a reciprocal increase in numbers released,
with consequent increase in cost. We do not specify how RIDL
males might be distributed so as to be available to mate essentially
at random with females in the wild population. The method(s) of
delivery would necessarily need to be designed to suit any
particular location. In cities there typically exists easy road access
on a fine scale, so distribution using vehicles could be straight-
forward. Agricultural SIT programs often use aerial release,
sometimes with GPS guidance systems, requiring expensive
equipment and specialist personnel.
Like all models, our combined framework necessarily reflects a
simplified version of reality and our results should not be
interpreted as accurate predictions of outcomes in any specific
setting. Features such as seasonal variations might need to be
incorporated to obtain a reasonable fit to the incidence, epidemic
peaks and multi-annual period of dengue if validating against
a particular dataset. Our models capture the most essential
characteristics of mosquito population and dengue dynamics. The
growing body of literature on dengue is identifying further features
that appear also to be important, such as heterogeneities in
mosquito biting behavior, the contribution of human movement to
the spread of dengue, and the spatially and temporally focal nature
of transmission [48,49]. We are also constrained by the availability
of data. The characterization of density-dependent competition
among Aedes aegypti larvae is better than for other mosquito species,
but is based on a limited data set and subject to the assumptions
under which Dye’s model was statistically fitted to that data [50].
Refined cost estimates specific to the RIDL technology are not yet
available. Our cost model uses data for conventional SIT primarily
against agricultural pests. This will probably overestimate RIDL-
based SIT costs because the larger agricultural insect species and
use of dyes as markers both produce more waste material (which is
expensive to dispose of), and the cost to purchase, transport,
operate and keep secure a radiation source would not be incurred
by a genetic control program. Conversely, the information often
excludes or is unclear on costs of distributing the released insects
(see Supporting Information S1) so our formula will underestimate
operational costs in that respect. Our costs will also be overstated
because we have not accounted for any reduction in conventional
vector control costs, because of lack of detailed information.
In keeping the model relatively simple, we have ignored other
possible epidemiological benefits. We assumed a constant case
fatality rate, but this depends on the quality of care and the stage
at which the patient is admitted to hospital. Hospitals can be
overwhelmed during periods of intense epidemic transmission (for
example, in April 2008 military support was called on to expand
care beyond beleaguered public hospitals in Rio de Janeiro, Brazil)
and patient management may suffer at such times. By reducing the
number of hospital admissions during peak dengue periods, the
vector control strategy might also decrease case fatality rates and
thus save further lives. The sheer scale of an epidemic can also
have implications for other health costs and services; for example,
the dengue outbreak in North Queensland, Australia, in 2008/9
led to shortages of blood supplies at blood donor centers [51].
The undiscounted cost per case averted during a fixed period is
a crude measure of cost-effectiveness of a health intervention. The
World Development Report ‘‘Investing in Health’’ [52] makes
extensive use of the Disability Adjusted Life Year (DALY) lost, a
key measure of the burden of disease, to judge which health
improving interventions deserve the highest priority for public
action. The DALY reflects the total amount of healthy life lost to
premature mortality or disability, taking into account how far into
the future the loss occurs and weighting the relative importance of
healthy life at different ages [53]. Eliminating the disease averts all
the lost DALYs. For an assessment quantifying the DALYS gained
(including beyond the end of the control program), either the
model would have to be expanded to include the age structure of
the host population or a reasonable estimate of stable age dis-
tribution at onset would be needed. Also, the amount and timing
of cash flows associated with program costs should be discounted
to present values using an appropriate risk-adjusted discount rate.
More sophisticated model components could bring in other
elements, such as spatial structure in human and vector popu-
lations, variation in biting rates, seasonal fluctuations, or changes
in host behavior (e.g. relaxing control efforts), according to what
were deemed key features for the purpose of the question to be
addressed. Better data would be needed to parameterize and
validate such models properly, and the additional detail would
potentially affect more than one component of the framework; for
example, good information about vector populations over space
and time requires adequate entomological surveillance and those
monitoring activities will have associated costs.
Extension of our analysis could be customized to relevant
country- or region-specific epidemiological, entomological, health-
care and economic data. Appropriate scenarios could be simulated,
detailed estimates of constructing and operating a sterile mosquito
release program could be prepared for a production facility of
appropriate size and location, the projected DALYs saved could be
valued at the per capita Gross National Income, and the effect on
the wider impact of dengue on that economy could be assessed. In
practice, such a wealth of specific data is unlikely to be available and
an accurate fully inclusive cost-benefit analysis seems infeasible at
least in the shorter term. However, preliminary approaches using
available data could be used to identify the parameter values and
other estimates to which the conclusions are most sensitive and to
direct experimental, ecological, economic and other studies towards
filling those key knowledge gaps.
The study presented here indicates that this genetic vector
control strategy has the potential to be a cost-effective interven-
tion. Deterministic models provide an appropriate framework for
the purpose of preliminary assessment, and predictions from these
models demonstrate the importance of key parameters (such as the
mean number of vectors per host, which directly affects release
numbers and hence costs). This information is likely to be highly
relevant for future analysis. For example, in practice the actual
numbers of RIDL males released and the release interval are likely
to vary around planned values because of production variation,
operational management, labor and equipment capacity, the
weather and other factors. Prospective stakeholders will be
interested in the chance of failure due to such fluctuations, and
what planned capacity, release rate and release interval would be
required to give at least a specified chance (e.g., 95%) of achieving
a particular objective (e.g., no reported locally transmitted dengue
infections) by a target date. Such questions could be investigated
using a risk-modeling simulation approach that builds on the
understanding gained from the present study.
The framework demonstrated here could be adapted to apply to
other diseases (or combination of diseases vectored by the same
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vaccine or other interventions), or variant or alternative genetic
technologies (for example, a program releasing Ae. aegypti RIDL
eggs into natural breeding sites, or strategies aimed at converting
the vector population to insects that are refractory to disease
transmission).
Although there has been a focus on economic arguments for
control of vector-borne diseases, there are wider potential benefits
to society, such as environmental improvements from reduced
insecticide use. Funding, technical and other support from
governments and international agencies is likely to be prominent
in any successful large-scale elimination of vector-borne disease.
Tackling infectious diseases relates to several of the UN’s
Millennium Development Goals, to reduce child mortality,
improve maternal health, combat diseases such as malaria,
eradicate extreme poverty and hunger, and achieve universal
primary education [54]. The control of diseases such as dengue
and malaria is a humanitarian goal that addresses the basic human
right to a healthy life.
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